Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Stock Information for Blue Horizon Global Capital Corp Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Blue Horizon Global Capital Corp Com

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
Mesabi Trust Press Release
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
Mesabi Trust Press Release
Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.